Arab Journal of Gastroenterology
Volume 10, Issue 1 , Pages 1-3 , March 2009

Antischistosomal therapy: Current status and recent developments

References 

  1. Abdel Wahab MF. Schistosomiasis in Egypt. Boca Raton, Florida, USA: CRC Press, Inc.; 1982;
  2. Abdel Wahab MF, Strickland GT, El Sahly A, et al. Schistosomiasis mansoni in an Egyptian village in the Nile Delta. Am J Trop Med Hyg. 1980;29(5):868–874
  3. Chen Z, Zhou XN, Yang K, et al. Strategy formulation for Schistosomiasis japonica control in different environmental settings supported by spatial analysis: a case study from China. Geospat Health. 2007;1(2):223–231
  4. Strickland GT, Ramirez BL. Schistosomiasis. In:  Hunter GW,  Thomas SG,  Strickland GT, et al. editor. Hunter’s tropical medicine and emerging infectious diseases. 8th ed.. W.B. Saunders Company; 2000;p. 804–831
  5. Scott JA. The incidence and distribution of the human schistosomes in Egypt. Am J Hyg. 1937;25(3):566–614
  6. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–891
  7. Shekhar KC. Schistosomiasis drug therapy and treatment considerations. Drugs. 1991;42(3):379–405
  8. Cioli D. Chemotherapy of schistosomiasis: an update. Parasitol Today. 1998;14(10):418–422
  9. McMahon JE. A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium. Ann Trop Med Parasitol. 1983;77(2):139–142
  10. Picquet M, Vercruysse J, Shaw DJ, et al. Efficacy of praziquantel against Schistosoma mansoni in Northern Senegal. Trans R Soc Trop Med Hyg. 1998;92(1):90–93
  11. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–667
  12. El Guiniady MA, el Touny MA, Abdel Bary MA, et al. Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg. 1994;51(6):809–818
  13. Helmi AH, Abdel Hadi AA, El Shanawani F, et al. The pharmacological approach to reverse portal hypertension and hepatic schistosomal fibrosis in Egypt. J Egypt Soc Parasitol. 2005;35(3):731–750
  14. Cioli D, Valle C, Angelucci F, et al. Will new antischistosomal drugs finally emerge?. Trends Parasitol. 2008;24(9):379–382
  15. Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999;60(6):932–935
  16. Danso Appiah A, Utzinger J, Liu J, et al. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;(3):CD000053
  17. Gryseels B, Mbaye A, De Vlas SJ, et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health. 2001;6(11):864–873
  18. Kohler P, Davies KP, Zahner H. Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992;51(3–4):195–211
  19. Benson AB. Oltipraz: a laboratory and clinical review. J Cell Biochem Suppl. 1993;17F:278–291
  20. Doenhoff MJ, Kusel JR, Coles GC, et al. Resistance of Schistosoma mansoni to praziquantel: is there a problem?. Trans R Soc Trop Med Hyg. 2002;96(5):465–469
  21. Sheir Z, Nasr AA, Massoud A, et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg. 2001;65(6):700–704
  22. Barakat R, Elmorshedy H, Fenwick A. Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. Am J Trop Med Hyg. 2005;73(2):365–367
  23. Botros S, Sayed H, El Dusoki H, et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am J Trop Med Hyg. 2005;72(2):119–123
  24. Xiao SH, Booth M, Tanner M. The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol Today. 2000;16(3):122–126
  25. Utzinger J, N’Goran EK, N’Dri A, et al. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 2000;355(9212):1320–1325
  26. De Oliveira Penido ML, Zech Coelho PM, de Mello RT, et al. Antischistosomal activity of aminoalkanethiols, aminoalkanethiosulfuric acids and the corresponding disulfides. Acta Trop. 2008;108(2-3):249–255
  27. Utzinger J, Xiao SH, Tanner M, et al. Artemisinins for schistosomiasis and beyond. Curr Opin Invest Drugs. 2007;8(2):105–116
  28. Ebisawa I. Epidemiology and eradication of Schistosomiasis japonica in Japan. J Travel Med. 1998;5(1):33–35
  29. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008;21(1):225–242
  30. Butterworth AE, Sturrock RF, Ouma JH, et al. Comparison of different chemotherapy strategies against Schistosoma mansoni in Machakos District, Kenya: effects on human infection and morbidity. Parasitology. 1991;103 Pt 3:339–355
  31. Olveda RM, Daniel BL, Ramirez BD, et al. Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission and morbidity. J Infect Dis. 1996;174(1):163–172
  32. El Bassiouni EA, Helmy MH, Saad EI, et al. Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether. Br J Biomed Sci. 2007;64(4):168–174

PII: S1687-1979(09)00008-2

doi: 10.1016/j.ajg.2009.03.002

Arab Journal of Gastroenterology
Volume 10, Issue 1 , Pages 1-3 , March 2009

Article Tools